The Bidirectional Association between Inflammatory Bowel Disease and Atopic Dermatitis: A Systematic Review and Meta-Analysis

Dermatology ◽  
2020 ◽  
Vol 236 (6) ◽  
pp. 546-553 ◽  
Author(s):  
Xiao Shi ◽  
Qi Chen ◽  
Fen Wang
Keyword(s):  
Systematic Review ◽  
Inflammatory Bowel Disease ◽  
Atopic Dermatitis ◽  
Bowel Disease ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Bidirectional Association ◽  
Newcastle Ottawa Scale ◽  
Inflammatory Bowel ◽  
Underlying Mechanisms

<b><i>Background:</i></b> Previous investigations have suggested a significant association between inflammatory bowel disease (IBD) and atopic dermatitis (AD). Yet, outcomes published remain inconsistent. <b><i>Objective:</i></b> To explore the association between IBD and AD by a systematic review and meta-analysis. <b><i>Methods:</i></b> A comprehensive search of studies published from March 1, 1968, to July 26, 2019, was performed in electronic databases as follows: PubMed, Embase, Cochrane Library, and Web of Science. Methodological quality was assessed based on the Newcastle-Ottawa Scale. Data analysis was conducted using R version 3.6.1 (meta package version 4.9-7). <b><i>Results:</i></b> A total of 14 studies were eligible for exploring the association between IBD and AD. Statistically significant differences were found on the risk of AD comorbidity among patients with IBD (risk ratio [RR] 1.83, 95% CI 1.39–2.40), Crohn’s disease (CD; RR 2.06, 95% CI 1.61–2.64), and ulcerative colitis (UC; RR 1.66, 95% CI 1.23–2.24). Compared with non-AD subjects, patients with AD were 48% (<i>p</i> = 0.019), 44% (<i>p</i> = 0.002), and 38% (<i>p</i> = 0.000) more likely to exhibit IBD, CD as well as UC, respectively. <b><i>Discussion:</i></b> Our evidence supported a significant bidirectional association between IBD and AD. Future prospective studies are warranted to explore underlying mechanisms linking them.

scholarly journals A Systematic Review and Meta-analysis of Paediatric Inflammatory Bowel Disease Incidence and Prevalence Across Europe

2020 ◽  
Vol 14 (8) ◽  
pp. 1119-1148 ◽  
Author(s):  
S E Roberts ◽  
K Thorne ◽  
N Thapar ◽  
I Broekaert ◽  
M A Benninga ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inflammatory Bowel Disease ◽  
Czech Republic ◽  
Bowel Disease ◽  
Meta Analysis ◽  
Grey Literature ◽  
Incidence Rates ◽  
Cochrane Library ◽  
The Czech Republic ◽  
Inflammatory Bowel

Abstract Background and Aims Inflammatory bowel disease [IBD] is often one of the most devastating and debilitating chronic gastrointestinal disorders in children and adolescents. The main objectives here were to systematically review the incidence and prevalence of paediatric IBD across all 51 European states. Methods We undertook a systematic review and meta-analysis based on PubMed, CINAHL, the Cochrane Library, searches of reference lists, grey literature and websites, covering the period from 1970 to 2018. Results Incidence rates for both paediatric Crohn’s disease [CD] and ulcerative colitis [UC] were higher in northern Europe than in other European regions. There have been large increases in the incidence of both paediatric CD and UC over the last 50 years, which appear widespread across Europe. The largest increases for CD have been reported from Sweden, Wales, England, the Czech Republic, Denmark and Hungary, and for UC from the Czech Republic, Ireland, Sweden and Hungary. Incidence rates for paediatric CD have increased up to 9 or 10 per 100 000 population in parts of Europe, including Scandinavia, while rates for paediatric UC are often slightly lower than for CD. Prevalence reported for CD ranged from 8.2 per 100 000 to approximately 60 and, for UC, from 8.3 to approximately 30. Conclusions The incidence of paediatric IBD continues to increase throughout Europe. There is stronger evidence of a north–south than an east–west gradient in incidence across Europe. Further prospective studies are needed, preferably multinational and based on IBD registries, using standardized definitions, methodology and timescales.

DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

2020 ◽  
Vol 57 (3) ◽  
pp. 232-243 ◽  
Author(s):  
Natália Sousa Freitas QUEIROZ ◽  
Rogerio SAAD-HOSSNE ◽  
Renata de Sá Brito FRÓES ◽  
Francisco Guilherme Cancela e PENNA ◽  
Stefania Burjack GABRIEL ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inflammatory Bowel Disease ◽  
Adverse Events ◽  
Bowel Disease ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Drug Discontinuation ◽  
Nocebo Effect ◽  
Inflammatory Bowel ◽  
Nocebo Effects

ABSTRACT BACKGROUND: Biologics have revolutionized the treatment of inflammatory bowel disease (IBD). However, these drugs had a significant influence on treatment-related costs, which resulted in the development of biosimilars. OBJECTIVE: This systematic review and meta-analysis aimed to evaluate the drug discontinuation rate in the IBD population who switched from originator to biosimilars in real-world switching studies and address potential nocebo effects as reasons for drug discontinuation. METHODS: Medline (via PubMed), EMBASE, Cochrane Library, and abstract databases of selected congresses were screened for reports of monoclonal antibody (mAb) switching with a minimum post-switch follow-up of >6 months or three infusions. All available information on discontinuation rates was assessed. RESULTS: A total of 30 observational studies were included, involving 3,594 patients with IBD. Twenty-six studies reported a switch from infliximab to CT-P13, two studies involved a switch to SB2, and switching information was not available in two studies. The discontinuation rates were 8%, 14%, and 21% at 6, 12, and 24 months, respectively. The main reasons for drug discontinuation and their respective risks were: disease worsening (2%), remission (4%), loss of adherence (4%), adverse events (5%), and loss of response (7%). The quality of the evidence ranged from low to very low depending on the outcome analyzed. Subjective symptoms leading to drug discontinuation were infrequently reported, and the nocebo effect was clearly assessed in just one of the included papers. CONCLUSION: Discontinuation rates following a switch to a biosimilar in patients with IBD increase over time. However, it was not possible to confirm the nocebo effect as a reason for discontinuation. Therefore, long-term studies evaluating the use of biosimilars to monitor adverse events and potential nocebo effects in post-marketing surveillance are still needed.

Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis

2019 ◽  
Vol 14 (3) ◽  
pp. 351-360 ◽  
Author(s):  
Farzad Alinaghi ◽  
Hasan Göcker Tekin ◽  
Johan Burisch ◽  
Jashin J Wu ◽  
Jacob P Thyssen ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Data Extraction ◽  
Meta Analysis ◽  
Epidemiological Studies ◽  
Diagnostic Process ◽  
Bidirectional Association ◽  
Newcastle Ottawa Scale ◽  
Inflammatory Bowel ◽  
Bidirectional Associations

Abstract Background and Aims Epidemiological studies have established an association between psoriasis and inflammatory bowel disease [IBD], i.e. ulcerative colitis [UC] and Crohn’s disease [CD], but results are inconsistent. The aim of this study was therefore to quantify the prevalences and association between IBD and psoriasis. Methods PubMed, Web of Science, and EMBASE were searched from database inception through April 2018 for studies reporting data on psoriasis among patients with IBD and vice versa. Meta-analysis was performed to estimate, respectively, the prevalences and association between IBD and psoriasis. Data extraction was according to the PRISMA guideline, and quality assessment was made using the Newcastle-Ottawa Scale. The main outcomes were the proportion of psoriasis patients with IBD and vice versa, as well as the association (odds ratio [OR]) of IBD in psoriasis and psoriasis in IBD, respectively. Results Based on quantitative analysis of 93 studies, the prevalence of psoriasis in CD and in UC was 3.6% (95% confidence interval [CI] 3.1%–4.6%) and 2.8% [95% CI 2.0%–3.8%] respectively. The prevalence of CD and UC was 0.7% [95% CI 0.2%–1.3%] and 0.5% [95% CI 0.3%–0.8%], respectively, among patients with psoriasis. Presence of CD or UC was significantly associated with psoriasis, with OR 2.0 [95% CI 1.4–2.9] and OR 1.5 [95% CI 1.2–2.0], respectively. Presence of psoriasis was significantly associated with CD: OR 2.2 [95% CI 1.6–3.1] and with UC: OR 1.6 [95% CI 1.3–2.0]. Conclusions We found significant bidirectional associations between psoriasis and IBD, warranting increased awareness among clinicians in the diagnostic process, especially in children and adolescents with IBD. Last, this study showed an increased frequency of paradoxical psoriasis in patients treated with biologics.

scholarly journals Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis

2016 ◽  
Vol 2016 ◽  
pp. 1-18 ◽  
Author(s):  
Chelle L. Wheat ◽  
Kindra Clark-Snustad ◽  
Beth Devine ◽  
David Grembowski ◽  
Timothy A. Thornton ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Inflammatory Bowel Disease ◽  
Incidence Rate ◽  
Bowel Disease ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Increased Risk ◽  
Inflammatory Bowel ◽  
Substantial Heterogeneity

Background/Aims. Inflammatory bowel disease (IBD) is associated with an increased risk of colorectal cancer (CRC). In addition, there may be an association between leukemia and lymphoma and IBD. We conducted a systematic review and meta-analysis of the IBD literature to estimate the incidence of CRC, leukemia, and lymphoma in adult IBD patients.Methods. Studies were identified by a literature search of PubMed, Cochrane Library, Medline, Web of Science, Scopus, EMBASE, and ProQuest Dissertations and Theses. Pooled incidence rates (per 100,000 person-years [py]) were calculated through use of a random effects model, unless substantial heterogeneity prevented pooling of estimates. Several stratified analyses and metaregression were performed to explore potential study heterogeneity and bias.Results. Thirty-six articles fulfilled the inclusion criteria. For CRC, the pooled incidence rate in CD was 53.3/100,000 py (95% CI 46.3–60.3/100,000). The incidence of leukemia was 1.5/100,000 py (95% CI −0.06–3.0/100,000) in IBD, 0.3/100,000 py (95% CI −1.0–1.6/100,000) in CD, and 13.0/100,000 py (95% CI 5.8–20.3/100,000) in UC. For lymphoma, the pooled incidence rate in CD was 0.8/100,000 py (95% CI −0.4–2.1/100,000). Substantial heterogeneity prevented the pooling of other incidence estimates.Conclusion. The incidence of CRC, leukemia, and lymphoma in IBD is low.

scholarly journals Effectiveness and safety of acupuncture therapy for inflammatory bowel disease: a protocol of systematic review and meta-analysis

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e045090
Author(s):  
Yuan-Fang Zhou ◽  
Ning Sun ◽  
Shi-Rui Cheng ◽  
Xiao-Dong Deng ◽  
Xiang-Yin Ye ◽  
...  
Keyword(s):  
Systematic Review ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Data Extraction ◽  
Meta Analysis ◽  
Biomedical Literature ◽  
Cochrane Library ◽  
China National Knowledge Infrastructure ◽  
Inflammatory Bowel ◽  
Randomised Controlled

IntroductionPrevious reviews have suggested that the effectiveness of acupuncture for inflammatory bowel disease (IBD) has not well been demonstrated due to the limited randomised controlled trials (RCTs). In recent years, the growing research on acupuncture for IBD make it possible to conduct a further systematic review and synthesise more sufficient clinical data to evaluate the effectiveness and safety of acupuncture for IBD.Methods and analysisNine electronic databases without language restriction will be retrieved from inception to March 2021, including the Cochrane Library, MEDLINE, EMBASE, Ovid, the Allied and Complementary Medicine Database, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, the Chongqing Chinese Science and Technology Periodical Database and Wanfang Database. The RCTs on acupuncture for IBD will be included. The data screening, data extraction and the assessment of risk bias will be performed respectively by two reviewers. The quality of evidence will be evaluated by using the Grading of recommendation Assessment, Development and Evaluation application. The meta-analysis will be performed if heterogeneity analysis conducted on the RevMan software (V.5.3) is insignificant. The primary outcome was symptoms alleviation after acupuncture treatment or even in the follow-up.Ethics and disseminationEthical approval will not be needed because data of this review are not involved in patient’s information and privacy. The results will be published and diffused in a peer-reviewed journal or relative conferences.Trial registration numberCRD42020157903.

Fr546 INTERVENTIONS TO INCREASE VACCINATIONS RATES WITH INFLAMMATORY BOWEL DISEASE AND RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

2021 ◽  
Vol 160 (6) ◽  
pp. S-357
Author(s):  
Jalpa Patel ◽  
Dina Fakhouri ◽  
Mohamed Noureldin ◽  
Iris Kovar-Gough ◽  
Francis A. Farraye ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systematic Review ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Meta Analysis ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document